Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies

Title: Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies

Volume: 16 Issue: 35

Author(s): Michele Moschetta, Marta Cesca, Francesca Pretto and Raffaella Giavazzi

Affiliation:

Keywords: Angiogenesis, VEGF, Combination Therapy, Biomarker, Resistance, Toxicity, bevacizumab, Avastin, TKRI, sunitinib, GIST, pazopanib, EGFR, PDGFR, FGFR, CRC, NSCLC, ABT-869, Axitinib, BIBF1120, Brivanib, Cediranib, Dovitinib, Foretinib, Motesanib, Sorafenib, Vandetanib, Vatalanib, ZD6474, carboplatin, paclitaxel, trastuzumab, Radio-Immunotherapy, Tregs, TKRI therapy, PlGF, hypothyroidism, neuropathy

Abstract: Angiogenesis is associated with tumor development and malignancy and is a validated target for cancer treatment. Preclinical and clinical evidence substantiates the feasibility of combining angiogenesis inhibitors with conventional anticancer therapy. This review discusses recent progress in combining antiangiogenic drugs, mainly acting on the VEGF/VEGFR pathway, with chemotherapy and other conventional therapies. Strategies for the optimization of combination therapy and the selection of appropriate treatment regimens are examined. As new drugs are entering clinical trials, reliable biomarkers are needed to stratify patients for antiangiogenic therapy, to identify resistant patients and to monitor response to treatment.

Cite this article as:

Moschetta Michele, Cesca Marta, Pretto Francesca and Giavazzi Raffaella, Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies, Current Pharmaceutical Design 2010; 16 (35) . https://dx.doi.org/10.2174/138161210794455021